Tag: Saluda Medical
Saluda announces plans to present new EVOKE study data at NANS...
Saluda Medical has announced that its data will be presented at the upcoming North American Neuromodulation Society (NANS) annual meeting (18–21 January, Las Vegas,...
Saluda receives US FDA approval for MRI labelling of Evoke spinal...
Saluda Medical has announced that the US Food and Drug Administration (FDA) has approved magnetic resonance imaging (MRI) conditional labelling for its Evoke system,...
Health economic data show cost-dominance of Saluda’s EVOKE system over open-loop...
Saluda Medical has announced the publication of new health economic data in the Clinical Journal of Pain that provides “the strongest ever economic case” for the...
Saluda, Neuromod, Neuvotion secure funding rounds to boost neuromodulation technologies
This week, three companies developing novel neuromodulation technologies for use in the treatment of various neurological disorders have each separately announced the receipt of...
Saluda Medical announces presentation of 36-month EVOKE trial data at NANS...
Saluda Medical has announced that late-breaking data from the "landmark" EVOKE clinical trial was presented at the recent North American Neuromodulation Society (NANS) annual...
Saluda Medical initiates US commercialisation of Evoke spinal cord stimulation system
Saluda Medical has announced plans for a limited commercial release of its Evoke spinal cord stimulation (SCS) system in the USA, with a full commercial...
Saluda Medical presents data on 24-month holistic response to spinal cord...
Saluda Medical has announced that Steven Falowski (Argires-Marotti Neurosurgical Associates of Lancaster, Lancaster, USA) recently presented late-breaking 24-month data from the company’s EVOKE study at...
Saluda Medical raises US$125 million to boost Evoke spinal cord stimulation...
Saluda Medical has finalised US$125 million in equity financing, with the proceeds being used in part to operationalise and scale commercialisation of the company’s Evoke spinal...
Saluda Medical receives FDA approval for Evoke SCS system to treat...
Saluda Medical has announced that it has received full approval from the US Food and Drug Administration (FDA) for the Evoke spinal cord stimulation (SCS)...
Saluda announces sustained, long-term pain relief results with closed-loop SCS in...
Saluda Medical today announced long-term results from its double-blind, Level 1 EVOKE trial, which have been published in JAMA Neurology and demonstrate superior, sustained pain...
New study finds high responder rates for ECAP-controlled, closed-loop spinal cord...
A randomised, double-blind trial finds ECAP-controlled closed-loop spinal cord stimulation (SCS) statistically superior for the treatment of chronic pain, compared to open-loop stimulation. At...
Saluda Medical results of US Evoke pivotal study through 12 months...
Saluda Medical has announced The Lancet Neurology journal published results from the US pivotal study demonstrating its Evoke ECAP-controlled, closed-loop spinal cord stimulation (SCS)...
Saluda Medical announces European commercial launch of Evoke, the ECAP-controlled, closed-loop...
Saluda Medical has announced the award of CE mark and the European commercial launch of the Evoke ECAP-controlled, closed-loop spinal cord stimulation (SCS) system...
The clinical utility of evoked compound action potentials is echoed by...
New data from both the Evoke and Avalon studies reiterate the importance of objective neurophysiological measures and clinically meaningful outcomes. These studies evaluated the...
Saluda Medical raises US$75 million equity financing from Boston Scientific and...
Following the announcement of the debt financing with Medtronic, Saluda Medical has announced that it has secured US$75 million in equity financing from Boston...
Saluda Medical secures debt financing from Medtronic
Saluda Medical has announced that it has secured a four-year term loan agreement with Medtronic, to fund continued development of its Evoke ECAP-controlled, closed-loop...
Saluda Medical secures US$40 million in series D financing
Saluda Medical, a medical device company developing a platform of closed-loop neuromodulation technologies based on neural response to stimulation, has secured US$40 million in...
